Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418351 | 1.00 | GPR119 (0.51) | GPR119CYP11B2EIF2AK4OXTRAVPR1A | |
| SCHEMBL29418501 | 0.91 | CYP11B2 (0.55) | GPR119CYP11B2EIF2AK4POLBNAMPT | |
| SCHEMBL30599714 | 0.91 | CYP11B2 (0.55) | GPR119CYP11B2EIF2AK4POLBNAMPT | |
| SCHEMBL25223238 | 0.91 | CYP11B2 (0.55) | GPR119CYP11B2EIF2AK4POLBNAMPT | |
| SCHEMBL25222484 | 0.88 | CYP11B2 (0.59) | GPR119CYP11B2EIF2AK4NAMPTCYP3A4 | |
| SCHEMBL30599709 | 0.88 | CYP11B2 (0.59) | GPR119CYP11B2EIF2AK4NAMPTCYP3A4 | |
| SCHEMBL25209734 | 0.85 | GPR119 (0.54) | GPR119POLBMEN1KMT2ACYP3A4 | |
| SCHEMBL30599749 | 0.85 | GPR119 (0.54) | GPR119POLBMEN1KMT2ACYP3A4 | |
| SCHEMBL20510296 | 0.84 | GPR119 (0.52) | GPR119CYP11B2EIF2AK4EGLN2NAMPT | |
| SCHEMBL19693889 | 0.83 | GPR119 (0.51) | GPR119CYP11B2EIF2AK4OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | GPR119 1014/4885CYP11B2 3857/4885EIF2AK4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.